2019
DOI: 10.1515/ncrs-2019-0758
|View full text |Cite
|
Sign up to set email alerts
|

The crystal structure of 6-methyl-3,20-dioxo-19-norpregna-4,6-dien-17-yl acetate–2,4-dihydroxybenzoic acid (1/1), C30H36O8

Abstract: C30H36O8, monoclinic, P21 (no. 4), a = 10.899(2) Å, b = 11.002(2) Å, c = 11.847(2) Å, V = 1310.3(5) Å3, Z = 2, Rgt(F) = 0.0504, wRref(F2) = 0.1161, T = 163(2) K.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 12 publications
0
1
0
Order By: Relevance
“…A pharmaceutical cocrystal is a binary or multi-component crystal system formed by the combination of drug active ingredient (API) and cocrystal former (CCF) through hydrogen bonds or other weak interactions between molecules [ 8 , 9 , 10 ]. By selecting CCFs with different properties, the physicochemical properties of API can be improved or designed at the molecular level without changing its structure, which is very important to maintain the biological activity of API in vivo [ 11 , 12 , 13 , 14 ].…”
Section: Introductionmentioning
confidence: 99%
“…A pharmaceutical cocrystal is a binary or multi-component crystal system formed by the combination of drug active ingredient (API) and cocrystal former (CCF) through hydrogen bonds or other weak interactions between molecules [ 8 , 9 , 10 ]. By selecting CCFs with different properties, the physicochemical properties of API can be improved or designed at the molecular level without changing its structure, which is very important to maintain the biological activity of API in vivo [ 11 , 12 , 13 , 14 ].…”
Section: Introductionmentioning
confidence: 99%